Antibodies 2012, 1(2), 172-198; doi:10.3390/antib1020172
Cancer Immunotherapy by Retargeting of Immune Effector Cells via Recombinant Bispecific Antibody Constructs
1
Institute of Immunology, Medical Faculty Carl Gustav Carus, Technical University Dresden, Fetscherstr. 74, 01307 Dresden, Germany
2
The DFG research Center and Cluster of Excellence for Regenerative Therapies Dresden, Germany
â€
Present address: Translational Immunology Unit, German Cancer Research Center, NCT Building, Im Neuenheimer Feld 460, 69120 Heidelberg, Germany.
*
Author to whom correspondence should be addressed.
Received: 24 May 2012 / Revised: 27 June 2012 / Accepted: 10 July 2012 / Published: 18 July 2012
(This article belongs to the Special Issue Bispecific Antibodies for Dual Targeting Strategies)
Abstract
Immunotherapy has emerged as an alternative strategy to treat malignancies in addition to conventional radio- and chemotherapy. There has been a plethora of evidence that the immune system is able to control tumor outgrowth and a number of strategies have been put forward to utilize this ability for immunotherapy. However, some of these strategies have not been very efficient and their success has been limited by tumor evasion mechanisms. A promising approach to engage effector cells of the immune system overcoming some of the escape mechanisms has been introduced more than two decades ago. This approach is based on bispecific antibodies. Here we summarize the evolution of bispecific antibodies, their improvement, remaining obstacles and some controversial reports. View Full-Text
Figure 1
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
Share & Cite This Article
MDPI and ACS Style
Stamova, S.; Koristka, S.; Keil, J.; Arndt, C.; Feldmann, A.; Michalk, I.; Bartsch, H.; Bippes, C.C.; Schmitz, M.; Cartellieri, M.; Bachmann, M. Cancer Immunotherapy by Retargeting of Immune Effector Cells via Recombinant Bispecific Antibody Constructs. Antibodies 2012, 1, 172-198.
Related Articles
Article Metrics
Comments
[Return to top]
Antibodies
EISSN 2073-4468
Published by MDPI AG, Basel, Switzerland
RSS
E-Mail Table of Contents Alert